MX2015011905A - Uso de levocetirizina y montelukast en el tratamiento de la vasculitis. - Google Patents

Uso de levocetirizina y montelukast en el tratamiento de la vasculitis.

Info

Publication number
MX2015011905A
MX2015011905A MX2015011905A MX2015011905A MX2015011905A MX 2015011905 A MX2015011905 A MX 2015011905A MX 2015011905 A MX2015011905 A MX 2015011905A MX 2015011905 A MX2015011905 A MX 2015011905A MX 2015011905 A MX2015011905 A MX 2015011905A
Authority
MX
Mexico
Prior art keywords
formulations
methods
levocetirizine
montelukast
vasculitis
Prior art date
Application number
MX2015011905A
Other languages
English (en)
Inventor
Bruce Chandler May
Original Assignee
Inflammatory Response Res Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Inflammatory Response Res Inc filed Critical Inflammatory Response Res Inc
Publication of MX2015011905A publication Critical patent/MX2015011905A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/136—Amines having aromatic rings, e.g. ketamine, nortriptyline having the amino group directly attached to the aromatic ring, e.g. benzeneamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Abstract

Las modalidades descritas aquí incluyen métodos y formulaciones para tratar la vasculitis. Los métodos y formulaciones incluyen, pero no se limitan a, métodos y formulaciones para proporcionar concentraciones efectivas de levocetirizina y montelukast a un paciente que las necesite. Los métodos y formulaciones pueden comprender elementos de liberación convencional y/o modificada, que proporciona una liberación del fármaco al paciente.
MX2015011905A 2013-03-13 2014-03-07 Uso de levocetirizina y montelukast en el tratamiento de la vasculitis. MX2015011905A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201361780380P 2013-03-13 2013-03-13
PCT/US2014/021723 WO2014164285A2 (en) 2013-03-13 2014-03-07 Use of levocetirizine and montelukast in the treatment of vasculitis

Publications (1)

Publication Number Publication Date
MX2015011905A true MX2015011905A (es) 2016-01-08

Family

ID=51659295

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2015011905A MX2015011905A (es) 2013-03-13 2014-03-07 Uso de levocetirizina y montelukast en el tratamiento de la vasculitis.

Country Status (10)

Country Link
US (2) US9669025B2 (es)
EP (1) EP2968309A4 (es)
JP (1) JP2016512262A (es)
KR (1) KR20160125283A (es)
CN (1) CN105263579B (es)
AU (1) AU2014249534B2 (es)
CA (1) CA2901413A1 (es)
MX (1) MX2015011905A (es)
RU (1) RU2015134422A (es)
WO (1) WO2014164285A2 (es)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2011268342B2 (en) 2010-06-16 2014-12-04 IRR, Inc. Use of levocetirizine and montelukast in the treatment of influenza, common cold and inflammation
WO2014164282A1 (en) 2013-03-13 2014-10-09 Inflammatory Response Research, Inc. Use of levocetirizine and montelukast in the treatment of traumatic injury
CA2901421A1 (en) 2013-03-13 2014-10-09 Bruce Chandler May Use of levocetirizine and montelukast in the treatment of autoimmune disorders
KR20160125283A (ko) 2013-03-13 2016-10-31 인플래머토리 리스폰스 리서치, 아이엔씨. 레보세티리진 및 몬테루카스트의 혈관염의 치료 용도
WO2016044095A1 (en) 2014-09-15 2016-03-24 Inflammatory Response Research, Inc. Levocetirizine and montelukast in the treatment of inflammation mediated conditions
CA3052071A1 (en) * 2017-01-30 2018-08-02 Western New England University Thiol isomerases inhibitors and use thereof
CN110169969B (zh) * 2019-06-28 2022-05-27 南京医科大学 Mk571在制备预防和治疗心脏病药物中应用

Family Cites Families (55)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4801612A (en) 1986-07-03 1989-01-31 Regents Of The University Of California Method of inhibiting inflammatory response
US5211958A (en) 1987-11-30 1993-05-18 Gist-Brocades, N.V. Pharmaceutical composition and process for its preparation
US5147637A (en) 1988-06-07 1992-09-15 The Rockefeller University Method of inhibiting the influx of leukocytes into organs during sepsis or other trauma
WO1993009833A1 (en) 1991-11-14 1993-05-27 Alliance Pharmaceutical Corp. Method and apparatus for partial liquid ventilation using fluorocarbons
WO1995009652A1 (en) 1993-10-06 1995-04-13 The Kennedy Institute For Rheumatology Treatment of autoimmune and inflammatory disorders
IL131025A0 (en) 1997-01-24 2001-01-28 Autoimmune Inc Treatment of autoimmune disease using tolerization in combination with methotrexate
CZ301349B6 (cs) 1997-12-23 2010-01-27 Schering Corporation Prostredek k lécbe respiracních a kožních onemocnení, který obsahuje alespon jednoho antagonistu leukotrienu a alespon jedno antihistaminikum
US6384038B1 (en) 1998-04-14 2002-05-07 Sepracor Inc. Methods and compositions using cetirizine in combination with leukotriene inhibitors or decongestants
US20020052312A1 (en) 2000-05-30 2002-05-02 Reiss Theodore F. Combination therapy of chronic obstructive pulmonary disease using muscarinic receptor antagonists
BR0112818A (pt) 2000-07-28 2004-10-19 Immupharm Aps Processo de tratamento de sintomas do resfriado comum, rinite alérgica e infecções relacionadas com o trato respiratório
US7718198B2 (en) 2001-06-20 2010-05-18 Metaproteomics, Llc Treatment modalities for autoimmune diseases
CZ20033454A3 (cs) 2001-06-28 2004-08-18 Ucbáfarchimás@Áa Tableta obsahující cetirizin a pseudoefedrin
DE60227709D1 (de) 2001-06-29 2008-08-28 Ab Science Die verwendung von c-kithemmern zur behandlung von autoimmunerkrankungen
AU2003232805A1 (en) 2002-05-24 2003-12-12 Carl-Fr. Coester Pharmaceutical active substance combination and the use thereof
US7291331B1 (en) 2002-09-11 2007-11-06 La Jolla Institute For Allergy And Immunology Methods of treating OX40 medicated recall immune responses
WO2004080414A2 (en) 2003-03-12 2004-09-23 Mullally John P Composition and method for treating inflammations by reducing c-reactive protein
US7666417B2 (en) 2003-04-22 2010-02-23 Fred Hutchinson Cancer Research Center Methods and compositions for treating autoimmune diseases or conditions
US20060263350A1 (en) 2003-09-26 2006-11-23 Fairfield Clinical Trials Llc Combination antihistamine medication
WO2006010283A1 (en) 2004-07-28 2006-02-02 Universität Zürich Prevention and treatment of thrombus formation
SG165344A1 (en) * 2004-10-05 2010-10-28 Genentech Inc Method for treating vasculitis
US20070244128A1 (en) 2005-11-04 2007-10-18 Amira Pharmaceuticals, Inc. 5-lipoxygenase-activating protein (flap) inhibitors
US20070225285A1 (en) 2005-11-04 2007-09-27 Amira Pharmaceuticals, Inc. 5-lipoxygenase-activating protein (flap) inhibitors
WO2007056510A2 (en) 2005-11-09 2007-05-18 The Children's Hospital Of Philadelphia Chloride transport upregulation for the treatment of traumatic brain injury
AU2006329042B2 (en) 2005-12-21 2012-02-02 Meda Pharma Gmbh & Co Kg Combination of anticholinergics, glucocorticoids, beta2-agonists, PDE4 inhibitor and antileukotriene for the treatment of inflammatory diseases
US7589076B2 (en) 2006-05-18 2009-09-15 Pgx Health, Llc Substituted aryl piperidinylalkynyladenosines as A2AR agonists
EP2170317A4 (en) 2007-02-12 2011-03-23 Mike Nicolaou TREATMENT OF CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD), GASTRO-OESOPHAGEAL REFLUX DISEASE (GERD), FOOD ALLERGIES, AND OTHER DISEASES AND GASTROINTESTIN DISORDERS AFFECTED BY APPROPRIATE MANAGEMENT OF HISTAMINE USING A COMBINATION OF INHIBITORS HISTIDINE DECARBOXYLASE, MEDICAMEN
WO2008106429A2 (en) 2007-02-26 2008-09-04 Ironwood Pharmaceuticals, Inc. Methods and compositions for the treatment of heart failure and other disorders
EP2175856A4 (en) 2007-08-15 2011-08-24 Chemagis Ltd NOVEL PROCESS FOR THE PREPARATION OF HIGH-PURITY LEVOCETRIXIN AND ITS SALTS
US20090227018A1 (en) 2007-10-25 2009-09-10 Revalesio Corporation Compositions and methods for modulating cellular membrane-mediated intracellular signal transduction
EP2209769A1 (en) 2007-10-25 2010-07-28 Merck Frosst Canada Ltd. Novel crystalline salts of montelukast
EP2215260A4 (en) 2007-10-25 2011-04-20 Revalesio Corp COMPOSITIONS AND METHOD FOR MODULATING CELL MEMBRANE-IMPROVED INTRA-CELLULAR SIGNAL TRANSMISSION
EP2403845B1 (en) 2009-03-02 2014-04-30 Generics [UK] Limited Improved process
WO2010107404A1 (en) 2009-03-16 2010-09-23 Mahmut Bilgic Stable pharmaceutical combinations
US8263581B2 (en) 2009-07-03 2012-09-11 Jdp Therapeutics, Inc. Non-sedating antihistamine injection formulations and methods of use thereof
GB2474748B (en) 2009-10-01 2011-10-12 Amira Pharmaceuticals Inc Polycyclic compounds as lysophosphatidic acid receptor antagonists
KR20120123691A (ko) 2010-01-28 2012-11-09 머크 샤프 앤드 돔 코포레이션 통증 및 기타의 적응증의 치료를 위한 제약 조성물
AU2011268342B2 (en) 2010-06-16 2014-12-04 IRR, Inc. Use of levocetirizine and montelukast in the treatment of influenza, common cold and inflammation
JP2013535456A (ja) 2010-07-28 2013-09-12 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 呼吸器系及び炎症性疾患の治療用医薬組成物
TR201009398A2 (tr) 2010-11-11 2012-05-21 Bi̇lgi̇ç Mahmut Fiziksel özellikleri geliştirilmiş tablet formülasyonları
WO2012092594A2 (en) 2010-12-30 2012-07-05 Harish Ziv M D Preparations for topical prevention and/or treatment of oral allergic symptoms due to oral contact with fruits and/or vegetables
US20130030009A1 (en) 2010-12-30 2013-01-31 Ziv Harish Method for the treatment and/or prevention of oral allergic symptions of the lips due to oral contact with a food allergen
JP2014511879A (ja) 2011-04-13 2014-05-19 レバレジオ コーポレイション 炎症性神経変性疾患に関与するエフェクターｔ細胞を抑制および／または調節する組成物および方法
EP2520292A1 (en) * 2011-05-06 2012-11-07 Helmholtz-Zentrum für Infektionsforschung GmbH Use of spirangiens for the treatment or prevention of IL-8 or IL-6 mediated disorders
KR20130009553A (ko) 2011-07-15 2013-01-23 한미약품 주식회사 몬테루카스트 또는 이의 약학적으로 허용가능한 염 및 레보세티리진 또는 이의 약학적으로 허용가능한 염을 함유하는 캡슐 제제
CN103827090B (zh) 2011-07-26 2016-04-20 勃林格殷格翰国际有限公司 取代的喹啉及其作为药物的用途
CN102895661A (zh) 2011-07-28 2013-01-30 中国科学院上海药物研究所 靶向CysLT1的药物在制备用于预防或治疗自身免疫性疾病的药物中的用途
WO2013148366A1 (en) 2012-03-27 2013-10-03 Duke Unversity Compositions and methods for the prevention and treatment of mast cell-induced vascular leakage
CN103505731A (zh) 2012-06-15 2014-01-15 中国药科大学 1型半胱氨酰白三烯受体拮抗剂在制备用于治疗阿尔茨海默病的药物中的用途
US20150322049A1 (en) 2012-12-13 2015-11-12 Ludwig Aigner Leukotriene pathway antagonists for the treatment of dementia, cognitive deficits in parkinson's disease and/or learning and memory deficiencies in parkinson's disease
KR20160125283A (ko) 2013-03-13 2016-10-31 인플래머토리 리스폰스 리서치, 아이엔씨. 레보세티리진 및 몬테루카스트의 혈관염의 치료 용도
CA2901421A1 (en) 2013-03-13 2014-10-09 Bruce Chandler May Use of levocetirizine and montelukast in the treatment of autoimmune disorders
EP2969001B1 (en) 2013-03-13 2018-12-19 IRR, Inc. Use of levocetirizine and montelukast in the treatment of anaphylaxis
WO2014164282A1 (en) 2013-03-13 2014-10-09 Inflammatory Response Research, Inc. Use of levocetirizine and montelukast in the treatment of traumatic injury
WO2016044095A1 (en) 2014-09-15 2016-03-24 Inflammatory Response Research, Inc. Levocetirizine and montelukast in the treatment of inflammation mediated conditions
WO2017210417A1 (en) 2016-06-03 2017-12-07 Inflammatory Response Research, Inc. Levocetirizine and montelukast in the treatment of radiation-mediated conditions

Also Published As

Publication number Publication date
RU2015134422A (ru) 2017-04-18
EP2968309A4 (en) 2016-08-31
US9669025B2 (en) 2017-06-06
WO2014164285A2 (en) 2014-10-09
CA2901413A1 (en) 2014-10-09
CN105263579A (zh) 2016-01-20
AU2014249534A1 (en) 2015-08-27
KR20160125283A (ko) 2016-10-31
EP2968309A2 (en) 2016-01-20
US10206919B2 (en) 2019-02-19
US20170231980A1 (en) 2017-08-17
JP2016512262A (ja) 2016-04-25
US20150352101A1 (en) 2015-12-10
WO2014164285A3 (en) 2015-10-29
CN105263579B (zh) 2020-01-10
AU2014249534B2 (en) 2018-08-30

Similar Documents

Publication Publication Date Title
MX2015012322A (es) Uso de levocetirizina y montelukast en el tratamiento de trastornos autoinmunes.
MX352824B (es) Uso de levocetirizina y montelukast en el tratamiento de influenza, resfriado común e inflamación.
PH12017502154A1 (en) Methods for conditioning patients for t cell therapy
MX2015011905A (es) Uso de levocetirizina y montelukast en el tratamiento de la vasculitis.
MX2021000071A (es) Uso de pridopidina para mejorar la funcion cognitiva y para tratamiento de enfermedad de alzheimer.
MX2015012315A (es) Uso de levocetirizina y montelukast en el tratamiento de lesion traumatica.
MX2015011775A (es) Uso de levocetirizina y montelukast en el tratamiento de anafilaxis.
IN2015DN00450A (es)
MX2022009155A (es) Nuevos profarmacos polimericos de la hormona del crecimiento humana (hgh).
PH12016500863A1 (en) Tetracyclic autotaxin inhibitors
PH12016502233A1 (en) (s)-pirlindole or its pharmaceutically acceptable salts for use in medicine
PH12017500392A1 (en) Medical treatments based on anamorelin
MX2015010296A (es) Tratamiento de formas progresivas de esclerosis multiple con laquinimod.
PH12016502236A1 (en) (r)-pirlindole and its pharmaceutically acceptable salts for use in medicine
MX2015013755A (es) Formulacion farmaceutica para uso en el tratamiento y/o prevencion de restenosis.
MX2017015424A (es) Nanoparticulas para su uso como vacuna terapeutica.
PH12016501101A1 (en) Veliparib in combination with carboplatin for the treatment of triple negative breast cancer